Health Essentials

Blogs

Kineret, a biologic drug, can prevent gout flare-ups

Kineret, a biologic drug, can prevent gout flare-ups

Gout is a prevalent type of auto-inflammatory arthritis that develops when MSU crystals accumulate in the synovial joints’ soft tissue. Acute gout flare-ups are marked by specific inflammatory symptoms such…
Read More
In older or less-fit CLL patients, first-line ibrutinib plus venetoclax improves outcomes

In older or less-fit CLL patients, first-line ibrutinib plus venetoclax improves outcomes

Ibrutinib, an oral BTK inhibitor taken once daily, is the only targeted treatment to show improved progression-free survival (PFS). Venetoclax is a single agent or combination with rituximab or obinutuzumab…
Read More
The management of Carbapenem-Resistant Acinetobacter baumannii Infections with Cefiderocol

The management of Carbapenem-Resistant Acinetobacter baumannii Infections with Cefiderocol

An opportunistic bacterial pathogen called Acinetobacter baumannii and it is predominantly linked to hospital infections. This new opportunistic infection has gained substantial notoriety because of a recent rise in occurrence.…
Read More
Anakinra's effectiveness in pericarditis: A systematic review

Anakinra’s effectiveness in pericarditis: A systematic review

Patient outcomes significantly improved as a result of anakinra. In addition, compared to conventional care, the pericarditis recovered more quickly and had a decreased risk of recurrence. Pericarditis, an inflammation…
Read More
The evolving role of Brentuximab Vedotin in classical Hodgkin Lymphoma

The evolving role of Brentuximab Vedotin in classical Hodgkin Lymphoma

With the introduction of Brentuximab Vedotin, a CD30-directed antibody-drug combination, the treatment strategy for people with classical Hodgkin lymphoma has changed. Since its first approval in 2011, BV has been…
Read More
High Dose Anakinra shows promise in treating CRS

High-Dose Anakinra shows promise in treating CRS/ICANS Post CAR T-Cell Therapy

The possibility of the cutting-edge therapeutic approach known as chimeric antigen receptor (CAR) T-cell immunotherapy to treat a variety of resistant haematological malignancies has attracted attention. The serious side effects…
Read More